Key Takeaways
- • Cinven, a London-based private equity fund, has expanded carried interest participation to all employees, including junior staff and support personnel, marking a departure from traditional tiered compensation structures in the industry.
- • The firm appointed new co-heads Jorge Quemada and Bruno Schick in December following the resignation of the previous CEO, whose departure was linked to regulatory scrutiny of the fund's prior operational practices.
- • Cinven faced a £52 million fine last year following investigation into a 2015 pharmaceutical deal (valued at £2.3 billion) where the fund had implemented a strategy of dramatically increasing niche drug prices sold to the NHS, with price increases reaching 6,000% over a 10-year period.
- • The fund has implemented structural reforms including expanded Monday morning investment team meetings open to junior employees and a new legal and compliance team of 17 people, positioning these changes as part of a "collaborating, doing deals, returning cash to investors" strategy.
Summary
Cinven, a prominent London private equity firm, has adopted a notably inclusive approach to carried interest distribution as part of a broader organizational restructuring following regulatory penalties and executive leadership changes. Under newly appointed co-heads Jorge Quemada and Bruno Schick—appointed in December after the previous chief executive's resignation—the fund has extended carried interest eligibility to all employees, including junior professionals and support staff, a significant departure from industry-standard practice where such distributions typically remain concentrated among senior investment partners.
The strategic shift reflects Cinven's effort to rehabilitate its reputation following sustained regulatory scrutiny. In 2015, Cinven sold a pharmaceutical group for £2.3 billion, which the fund characterized as "one of the most successful deals we've ever done." Subsequent investigation revealed that the fund's success had been built substantially on ratcheting up prices for niche pharmaceutical products that had escaped regulatory oversight, resulting in price increases reaching 6,000% over the decade-long holding period. The fund received a £52 million penalty last year as a direct consequence of this pricing strategy affecting NHS drug procurement.
Alongside compensation restructuring, Cinven has implemented operational transparency measures designed to accelerate junior employee development and engagement. The firm now holds regular Monday morning investment team meetings where junior staff attend and senior investment professionals explain investment theses, operational details, and exit processes. According to Quemada, this approach "helps, especially the more junior people, to get up on the learning curve very quickly." The fund has simultaneously built out its compliance infrastructure with a new legal and compliance team of 17 dedicated personnel, signaling prioritization of regulatory adherence under the new management regime.
These initiatives position Cinven's current strategy as fundamentally distinct from its pre-2024 operational framework, with explicit focus on collaborative deal execution and consistent investor cash returns rather than the price optimization tactics that drew regulatory attention. The timing reflects broader industry pressures around talent retention at junior levels, though Cinven's approach—combining expanded economic participation with institutional transparency—represents a notably progressive response within institutional private equity.
The strategic shift reflects Cinven's effort to rehabilitate its reputation following sustained regulatory scrutiny. In 2015, Cinven sold a pharmaceutical group for £2.3 billion, which the fund characterized as "one of the most successful deals we've ever done." Subsequent investigation revealed that the fund's success had been built substantially on ratcheting up prices for niche pharmaceutical products that had escaped regulatory oversight, resulting in price increases reaching 6,000% over the decade-long holding period. The fund received a £52 million penalty last year as a direct consequence of this pricing strategy affecting NHS drug procurement.
Alongside compensation restructuring, Cinven has implemented operational transparency measures designed to accelerate junior employee development and engagement. The firm now holds regular Monday morning investment team meetings where junior staff attend and senior investment professionals explain investment theses, operational details, and exit processes. According to Quemada, this approach "helps, especially the more junior people, to get up on the learning curve very quickly." The fund has simultaneously built out its compliance infrastructure with a new legal and compliance team of 17 dedicated personnel, signaling prioritization of regulatory adherence under the new management regime.
These initiatives position Cinven's current strategy as fundamentally distinct from its pre-2024 operational framework, with explicit focus on collaborative deal execution and consistent investor cash returns rather than the price optimization tactics that drew regulatory attention. The timing reflects broader industry pressures around talent retention at junior levels, though Cinven's approach—combining expanded economic participation with institutional transparency—represents a notably progressive response within institutional private equity.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.